Cutler Group LP Avadel Pharmaceuticals PLC Call Options Transaction History

Cutler Group LP

7 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q4 2022 Feb 07, 2023	BUY	$5.02 - $10.0 $14,055 - $28,000	2,800 Added 186.67%	4,300 $3,000
Q3 2022 Oct 25, 2022	SELL	$2.57 - $7.31 $85,324 - $242,692	-33,200 Reduced 95.68%	1,500 $1,000
Q2 2022 Aug 04, 2022	SELL	$1.07 - $6.95 $8,988 - $58,380	-8,400 Reduced 19.49%	34,700 $2,000
Q1 2022 Apr 14, 2022	BUY	$5.46 - $8.29 $223,860 - $339,889	41,000 Added 1952.38%	43,100 $56,000
Q4 2021 Jan 18, 2022	SELL	$7.34 - $11.18 $33,764 - $51,428	-4,600 Reduced 68.66%	2,100 $0
Q2 2020 Jul 22, 2020	BUY	$7.25 - $11.75 $26,825 - $43,475	3,700 Added 123.33%	6,700 $11,000
Q1 2020 May 07, 2020	BUY	$4.06 - $10.64 $12,179 - $31,920	3,000 New	3,000 $14,000

1.07M

Ticker AVDL
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 60,581,300
Market Cap $650M
Description
Avadel Pharmaceuticals plc operates as a biopharmaceutical company in the United States. Its lead product candidate is FT218, a formulation of sodium oxybate, which is in a Phase 3 clinical trial for the treatment of excessive daytime sleepiness and cataplexy in adults with narcolepsy. The company was formerly known as Flamel Technologies SA and...

Get notified when there are updates to the investment portfolio of Cutler Group LP, based on Form 13F filings with the SEC.

Stay updated on Cutler Group LP with notifications on news.